Pharmaceuticals & Biotech German Community

Zoetis sells medicines and vaccines for pets and farm animals, and long-term demand keeps rising as people treat pets more like family and as more households buy more meat and dairy. Recent worries around a key pet treatment have weighed on sentiment, but the business still looks hard to copy and built to keep growing—if those concerns don’t deepen.Read more

Item 1 – Business (what the company does) �Johnson & Johnson is a New Jersey–incorporated healthcare holding company with operating subsidiaries in virtually all countries and ~138,200 employees focused on human health and well‑being. �Operates in two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and technologies).Read more

Perspectivas de Mercado Olhando para o horizonte de 2026 e além, a Bayer AG emerge como uma empresa em transição estratégica, navegando por desafios persistentes enquanto aposta em inovação e eficiência operacional para impulsionar uma recuperação sustentável. Após um 2025 marcado por declínios em lucros e pressões litigiosas, a companhia projeta um retorno ao crescimento de lucros a partir de 2026, impulsionado por um pipeline robusto em farmacêuticos, otimizações em Crop Science e uma reestruturação interna que visa economias significativas.Read more

Ecco cosa dicono gli utili di Novo Nordisk del Q4 2024 Nonostante le azioni si trovino ai minimi degli ultimi 15 mesi e il sentiment generale sia un po' ribassista, i dati del Q4 offrono spunti interessanti. Il colosso farmaceutico europeo ha registrato un incremento del 30,1% nelle vendite , raggiungendo 11,48 miliardi EUR, superando così le attese.Read more

Demand for injectable medicines keeps rising, and SCHOTT Pharma aims to ride that wave by selling more premium, higher‑value packaging used in newer therapies. The upside comes from fast new factory ramp-ups and a push into greener materials, but investors should watch for weak demand in core products, heavy spending, and reliance on a small group of big drugmakers.Read more

Bayer’s crop science and drug businesses face a stubborn mix of lawsuits, tougher rules, and heavy debt that could keep squeezing its ability to invest and reward shareholders. At the same time, new medicines and stronger farm demand could help steady the business if legal risks ease faster than expected.Read more

Evotec leans harder into big drugmaker partnerships and a more “pick-and-shovel” role in biotech, aiming to earn steadier income from licensing and tech services instead of heavy spending on its own facilities. The upside comes from its push into AI-driven biology and personalized medicine, but the story can break if a few key partners pull back or biotech funding stays weak.Read more

Merck KGaA is leaning harder into its life science and healthcare businesses—helped by new products, a recent acquisition, and a push into digital tools—while stepping away from a lower-profit unit. But the path back to steady growth may be bumpy, with weakness in parts of its electronics business and looming competition and patent losses in key medicines.Read more

Gerresheimer is betting on a big purchase and new product lines to sell more high-end packaging and drug delivery tools, while upgrading factories to run more smoothly. The key question is whether it can pull off the integration and manage cash strain and demand swings without hurting day-to-day operations.Read more